Physician profile
John Gordon
NPI 1891727970
$3,704.53
in general payments reported to CMS, 2019-2025
24 companies · $118 in 2025
The $118 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $751 · 2020: $304 · 2021: $409 · 2022: $305 · 2023: $126 · 2024: $1,691 · 2025: $118.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,010 · Travel and Lodging: $925.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,009.90 |
| Travel and Lodging | $925.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axonics, INC. | $1,746.31 | 2023-2024 | Axonics |
| Abbvie INC. | $746.55 | 2019-2022 | |
| Hologic Sales and Service, LLC | $313.22 | 2019-2022 | |
| Astellas Pharma US INC | $158.08 | 2019-2025 | Veozah |
| Urovant Sciences INC | $93.62 | 2021-2022 | |
| Scynexis, INC. | $82.41 | 2022 | |
| Exeltis, USA INC. | $63.65 | 2021-2023 | Slynd |
| Myovant Sciences INC. | $53.29 | 2022 | |
| Daiichi Sankyo INC. | $43.28 | 2021 | |
| Novo Nordisk INC | $42.27 | 2025 | |
| Therapeuticsmd, INC. | $41.02 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $35.21 | 2019-2021 | |
| Duchesnay USA Incorporated | $34.73 | 2019 | |
| Lupin INC. | $33.90 | 2019 | |
| Pfizer INC. | $33.59 | 2023 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $26.00 | 2019-2022 | |
| Amgen INC. | $25.82 | 2020 | |
| Avion Pharmaceuticals | $24.55 | 2019-2020 | |
| Ethicon US, LLC | $23.21 | 2019 | |
| Roche Diagnostics Corporation | $19.71 | 2019 | |
| Bard Access Systems, INC. | $19.33 | 2019 | |
| Sumitomo Pharma America, INC. | $17.94 | 2025 | Gemtesa |
| Agile Therapeutics, INC. | $14.90 | 2024 | Twirla |
| Medtronic, INC. | $11.94 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Gordon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.